Updated August 2026

Cannabis rescheduling entered a new phase in 2026, creating potential tax and research benefits while leaving several major industry challenges unresolved.

In December 2025, President Donald Trump signed an executive order directing the attorney general to expedite the process of moving marijuana from Schedule I to Schedule III under the Controlled Substances Act.

The order did not reschedule marijuana by itself. Instead, it instructed federal agencies to accelerate the required administrative process.

Further action followed in April 2026. The Department of Justice placed FDA-approved marijuana products and products covered by qualifying state-issued medical cannabis licenses in Schedule III. At the same time, the government continued proceedings to consider the broader rescheduling of marijuana.

These developments represent meaningful federal recognition of cannabis’s medical use. However, rescheduling is not the same as legalization, and it does not automatically resolve banking, payments, interstate commerce, or other regulatory challenges.

Here is what cannabis rescheduling in 2026 means for operators, investors, researchers, and the wider industry.

What Is Cannabis Rescheduling?

The Controlled Substances Act classifies controlled substances into five schedules based on factors that include accepted medical use, potential for misuse, and risk of dependence.

Schedule I is the most restrictive category. It applies to substances the federal government considers to have no currently accepted medical use and a high potential for abuse.

Schedule III substances are recognized as having accepted medical applications and a lower potential for abuse than Schedule I or II drugs. However, they remain federally controlled.

Moving marijuana to Schedule III changes how the federal government treats qualifying cannabis activity. It does not make cannabis equivalent to an ordinary consumer product, remove every federal restriction, or legalize recreational marijuana nationwide.

What Changed in 2026?

Cannabis rescheduling has developed through several distinct federal actions.

President Trump’s December 2025 executive order also directed federal agencies to support medical marijuana and CBD research.

In April, the Department of Justice announced the immediate Schedule III treatment of qualifying medical products. The DEA then conducted hearings concerning broader marijuana rescheduling from June 29 through July 15, 2026.

As of August 2026, the government had not announced a final rule completing the broader transfer of all marijuana from Schedule I to Schedule III.

Potential Tax Relief Under Section 280E

One of the most important effects of Schedule III classification involves Internal Revenue Code Section 280E.

Section 280E prevents businesses trafficking in Schedule I or Schedule II controlled substances from deducting most ordinary business expenses from federal taxable income. Cannabis companies affected by the rule may be unable to deduct expenses such as rent, payroll, marketing, and administrative costs.

Because Section 280E applies specifically to Schedule I and II substances, qualifying cannabis activity moved to Schedule III may no longer be subject to the same restriction.

This could produce significant tax relief for eligible medical cannabis businesses. Companies may have more capital available for staffing, technology, expansion, compliance, and product development.

However, businesses should not assume that every operation immediately qualifies for relief. The April 2026 order applies to defined categories of medical marijuana products, while adult-use cannabis remains subject to different federal treatment.

Operators should consult qualified tax and legal professionals before changing their reporting practices. Eligibility may depend on the company’s licenses, products, activities, and applicable effective dates.

Rescheduling Could Expand Cannabis Research

Schedule I restrictions have historically made cannabis research difficult and expensive.

Researchers may need specialized registrations, security procedures, sourcing arrangements, and federal approvals before conducting studies involving Schedule I substances. These requirements can slow projects and discourage institutions from entering the field.

Schedule III treatment may reduce some of those barriers. It could allow researchers to conduct more extensive studies into cannabis dosing, safety, drug interactions, therapeutic applications, and long-term effects.

Improved research could also provide healthcare professionals and regulators with better information. Over time, this may support the development of standardized treatments and additional FDA-approved cannabis-based medications.

Schedule III classification does not eliminate research oversight. Researchers and manufacturers must still comply with DEA, FDA, and other federal requirements.

Rescheduling Does Not Equal Federal Legalization

Cannabis rescheduling and cannabis legalization are separate policy changes.

Schedule III substances remain controlled under federal law. Their manufacture, distribution, and dispensing are subject to federal regulations, and commercially available state cannabis products do not automatically become FDA-approved medications.

Rescheduling also does not create a national adult-use market. States will continue setting their own rules for licensing, testing, product limits, retail operations, and consumer access.

The change does not automatically permit interstate cannabis commerce either. Moving cannabis products across state lines may remain federally restricted even when both states have legal markets.

Operators must therefore continue following the laws and regulations that apply within each jurisdiction.

Will Rescheduling Solve Cannabis Banking?

Rescheduling may improve institutional confidence, but it does not automatically give cannabis businesses full access to traditional banking.

Banks and payment providers must consider the Bank Secrecy Act, anti-money-laundering rules, federal drug laws, and guidance from financial regulators. Adult-use cannabis activity remains particularly complicated because it has not been federally legalized.

Some banks may become more comfortable serving qualifying medical cannabis businesses following Schedule III treatment. Others may wait for additional guidance or congressional action before changing their policies.

In June 2026, lawmakers introduced a new SAFE Banking Act. The proposal would protect qualifying financial institutions that choose to serve cannabis businesses operating legally under state, tribal, or local law.

As of August 2026, that legislation had not become law.

Rescheduling and banking reform address different issues. Schedule III may reduce certain tax and research restrictions, while the SAFE Banking Act would create more direct protections for financial institutions.

What Rescheduling Means for Cannabis Payments

Payment processing will remain a specialized challenge even as federal policy evolves.

Rescheduling does not require mainstream card networks, banks, or general-purpose processors to serve cannabis businesses. Providers may continue applying their own underwriting standards and risk policies.

Operators should therefore avoid assuming that every conventional payment option will suddenly become available.

Cannabis businesses still need providers that understand licensing requirements, transaction monitoring, regulatory reporting, and the differences between medical and adult-use activity.

Payment redundancy also remains important. Relying entirely on one provider or payment method can expose a dispensary to operational disruptions if banking relationships, processor policies, or regulatory requirements change.

A flexible payment strategy may combine cash with appropriate digital payment options and backup systems. The right structure will depend on the business model, state market, customer preferences, and compliance requirements.

What Rescheduling Means for Investors

Schedule III treatment could make qualifying cannabis companies more attractive to investors by reducing tax burdens and signaling greater federal recognition of medical cannabis.

Improved cash flow could strengthen balance sheets and make it easier for companies to invest in growth. Additional research may also create opportunities for pharmaceutical development, clinical services, technology, and specialized professional support.

However, rescheduling does not eliminate investment risk.

Operators will continue facing state-by-state regulations, limited interstate commerce, competitive pricing, licensing costs, and restricted access to traditional capital. Investors should evaluate individual businesses based on their financial health and compliance practices instead of assuming that federal reform will benefit every company equally.

What Cannabis Businesses Should Do Now

Cannabis companies should prepare for continued regulatory change without basing their strategies on an assumed outcome.

Businesses should maintain accurate licenses, ownership records, financial statements, product information, and compliance documentation. Medical operators should also determine whether their activities fall within the categories affected by the April 2026 Schedule III order.

Tax strategies should be reviewed with qualified professionals before businesses claim deductions previously restricted by Section 280E. Operators should also monitor DEA proceedings, new Treasury guidance, state regulatory updates, and the progress of federal banking legislation.

Financial resilience remains essential. Businesses should evaluate their banking relationships, payment infrastructure, cash-management practices, and backup payment options before a disruption occurs.

What Happens Next?

The federal government’s next steps will determine how broadly Schedule III treatment applies across the cannabis industry.

The DEA must complete the administrative process associated with broader rescheduling. That process may include reviewing hearing testimony, evaluating evidence, addressing legal objections, and issuing a final decision.

Even if broader Schedule III status is finalized, additional federal guidance will be necessary. Agencies will need to clarify how the change affects taxation, research, enforcement, banking, and state-regulated cannabis activity.

Legal challenges may also affect the implementation timeline.

For cannabis businesses, the most practical approach is to monitor verified federal announcements rather than relying on predicted dates or political statements.

Conclusion

Cannabis rescheduling in 2026 represents a significant shift in federal policy, particularly for qualifying medical cannabis businesses.

The move may provide tax relief, expand research opportunities, and encourage greater participation from financial institutions. However, it does not legalize adult-use cannabis, authorize interstate commerce, guarantee banking access, or make state-regulated products FDA-approved.

The industry is entering a transitional period rather than reaching the end of federal reform.

Cannabis businesses that prioritize compliance, maintain accurate documentation, and build resilient financial infrastructure will be better prepared for whatever comes next.

PayRio provides payment solutions designed for cannabis and other regulated industries. To discuss building a stable payment strategy for your business, contact PayRio.